About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Urinary Tract Infection Therapeutics Market Size, Share | 2033
Urinary Tract Infection Therapeutics Market

Urinary Tract Infection Therapeutics Market Size, Share & Trends Analysis Report By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, Other Indications) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI3425DR
Last Updated : March 19, 2025
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Urinary Tract Infection Therapeutics Market Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Penicillin and Combinations
        1. By Value
      3. Quinolones
        1. By Value
      4. Cephalosporin
        1. By Value
      5. Azoles and Amphotericin B
        1. By Value
      6. Nitrofurans
        1. By Value
      7. Other Drugs
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Complicated UTI
        1. By Value
      3. Uncomplicated UTI
        1. By Value
      4. Other Indications
        1. By Value
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Penicillin and Combinations
        1. By Value
      3. Quinolones
        1. By Value
      4. Cephalosporin
        1. By Value
      5. Azoles and Amphotericin B
        1. By Value
      6. Nitrofurans
        1. By Value
      7. Other Drugs
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Complicated UTI
        1. By Value
      3. Uncomplicated UTI
        1. By Value
      4. Other Indications
        1. By Value
    4. U.S.
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Penicillin and Combinations
          1. By Value
        3. Quinolones
          1. By Value
        4. Cephalosporin
          1. By Value
        5. Azoles and Amphotericin B
          1. By Value
        6. Nitrofurans
          1. By Value
        7. Other Drugs
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Complicated UTI
          1. By Value
        3. Uncomplicated UTI
          1. By Value
        4. Other Indications
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Penicillin and Combinations
        1. By Value
      3. Quinolones
        1. By Value
      4. Cephalosporin
        1. By Value
      5. Azoles and Amphotericin B
        1. By Value
      6. Nitrofurans
        1. By Value
      7. Other Drugs
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Complicated UTI
        1. By Value
      3. Uncomplicated UTI
        1. By Value
      4. Other Indications
        1. By Value
    4. U.K.
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Penicillin and Combinations
          1. By Value
        3. Quinolones
          1. By Value
        4. Cephalosporin
          1. By Value
        5. Azoles and Amphotericin B
          1. By Value
        6. Nitrofurans
          1. By Value
        7. Other Drugs
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Complicated UTI
          1. By Value
        3. Uncomplicated UTI
          1. By Value
        4. Other Indications
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Penicillin and Combinations
        1. By Value
      3. Quinolones
        1. By Value
      4. Cephalosporin
        1. By Value
      5. Azoles and Amphotericin B
        1. By Value
      6. Nitrofurans
        1. By Value
      7. Other Drugs
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Complicated UTI
        1. By Value
      3. Uncomplicated UTI
        1. By Value
      4. Other Indications
        1. By Value
    4. China
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Penicillin and Combinations
          1. By Value
        3. Quinolones
          1. By Value
        4. Cephalosporin
          1. By Value
        5. Azoles and Amphotericin B
          1. By Value
        6. Nitrofurans
          1. By Value
        7. Other Drugs
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Complicated UTI
          1. By Value
        3. Uncomplicated UTI
          1. By Value
        4. Other Indications
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Penicillin and Combinations
        1. By Value
      3. Quinolones
        1. By Value
      4. Cephalosporin
        1. By Value
      5. Azoles and Amphotericin B
        1. By Value
      6. Nitrofurans
        1. By Value
      7. Other Drugs
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Complicated UTI
        1. By Value
      3. Uncomplicated UTI
        1. By Value
      4. Other Indications
        1. By Value
    4. UAE
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Penicillin and Combinations
          1. By Value
        3. Quinolones
          1. By Value
        4. Cephalosporin
          1. By Value
        5. Azoles and Amphotericin B
          1. By Value
        6. Nitrofurans
          1. By Value
        7. Other Drugs
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Complicated UTI
          1. By Value
        3. Uncomplicated UTI
          1. By Value
        4. Other Indications
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Penicillin and Combinations
        1. By Value
      3. Quinolones
        1. By Value
      4. Cephalosporin
        1. By Value
      5. Azoles and Amphotericin B
        1. By Value
      6. Nitrofurans
        1. By Value
      7. Other Drugs
        1. By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Complicated UTI
        1. By Value
      3. Uncomplicated UTI
        1. By Value
      4. Other Indications
        1. By Value
    4. Brazil
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Penicillin and Combinations
          1. By Value
        3. Quinolones
          1. By Value
        4. Cephalosporin
          1. By Value
        5. Azoles and Amphotericin B
          1. By Value
        6. Nitrofurans
          1. By Value
        7. Other Drugs
          1. By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Complicated UTI
          1. By Value
        3. Uncomplicated UTI
          1. By Value
        4. Other Indications
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Urinary Tract Infection Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. AstraZeneca
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bayer AG
    3. Cipla Inc.
    4. GlaxoSmithKline PLC
    5. Shionogi & Co. Ltd
    6. Novartis AG
    7. Pfizer.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Urinary Tract Infection Market Size The global urinary tract infection market size was valued at USD 9.55 billion in 2024 and is expected to grow from USD 9.85 billion in 2025 to USD 12.67 billion by 2033, growing at a CAGR of 3.2% during
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.